New England Journal of Medicine Publishes Positive Phase 3 Trial Results for REGEN-COV™ (casirivimab and imdevimab) to Treat COVID-19

TARRYTOWN, N.Y. , Sept. 29, 2021 /PRNewswire/ —  Regeneron Pharmaceuticals, Inc.  (NASDAQ: REGN) today announced that the New England Journal of Medicine ( NEJM ) published  positive detailed results from a Phase 3 trial that assessed the ability of REGEN-COV™ (casirivimab and imdevimab) to treat


Get every new post delivered right to your inbox.

Original Source